[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 2/3Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK) Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered with an Optimized Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Viroligically Suppressed Pediatric Subjects.

What is the purpose of the study? (in Layman's terms, please describe the study)

To evaluate the steady state pharmacokinetics (PK) and confirm the dose of cobicistat-boosted atazanavir (ATV/co) or cobicistat-boosted Darunavir (DRV/co) in HIV-1 antiretroviral experienced pediatric participants between the ages of 3 Months and less than 18 Years.

Upstate Institutional Review Board (IRB) Number:


Study/Protocol ID:


Study Phase:


Patient Age Group:


Principal Investigator:

Leonard B Weiner

ClinicalTrials.Gov ID:


For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Wendy A Holz
Phone: 315-464-7562
Email: [email protected]

Return to Previous Page || Search Again